Free Trial
LON:ETX

e-therapeutics (ETX) Share Price, News & Analysis

e-therapeutics logo

About e-therapeutics Stock (LON:ETX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
9
9
52-Week Range
N/A
Volume
2.52 million shs
Average Volume
758,869 shs
Market Capitalization
£52.59 million
P/E Ratio
N/A
Dividend Yield
3.35%
Price Target
N/A
Consensus Rating
N/A

Company Overview

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.

Receive ETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ETX Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
RBC Capital Releases a Buy Rating on Edgewise Therapeutics (EWTX)
See More Headlines

ETX Stock Analysis - Frequently Asked Questions

e-therapeutics plc (LON:ETX) announced its earnings results on Tuesday, March, 17th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.03.

Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that e-therapeutics investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), B&M European Value Retail (BME), Coats Group (COA), Eurasia Mining (EUA), genedrive (GDR) and Greencore Group (GNC).

Company Calendar

Last Earnings
3/17/2020
Today
4/27/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:ETX
CIK
N/A
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-10,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£295,000.00
Price / Cash Flow
5.07
Book Value
GBX 5 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
£52.59 million
Optionable
Not Optionable
Beta
0.46
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (LON:ETX) was last updated on 4/27/2025 by MarketBeat.com Staff
From Our Partners